Lilly Establishes New Injectable Medicine and Device ManufacturingLilly Chooses Pennsylvania for New Injectable Medicine and Device Manufacturing Facility Eli Lilly and Company today announced plans to invest more than $3.5 billion in a new manufacturing facility in the Lehigh Valley, Pennsylvania. The site…
ICON’s Accellacare Site Network Enhances Oncology Research Through New Cancer Institute Partnership ICON plc today announced a significant expansion of oncology research capabilities within its Accellacare Site Network through the opening of the Brian Moran Cancer Institute at Duly Health…
Bayer to Showcase New Phase III Data and Innovations in Radiology Portfolio at ECR 2026 Bayer will present advancements of its comprehensive radiology portfolio at the 2026 European Congress of Radiology (ECR) taking place from March 4-8, 2026, in Vienna,…
AbbVie Reports Phase 3 EPCORE® DLBCL-1 Topline Results for Epcoritamab in Relapsed/Refractory DLBCL AbbVie today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, compared to investigator’s choice of chemoimmunotherapy in…
University of Pennsylvania, BioNTech, and OUP Launch $50 Million Life Sciences Fund The University of Pennsylvania (“Penn”), BioNTech SE (“BioNTech”), and OUP (Osage University Partners) announced the launch of the $50 million Penn-BioNTech Innovative Therapeutics Seed Fund (“PxB Fund”), a dedicated venture…
Highlights recent progress across key R&D programs and outlines strategic priorities for 2026 Enanta Pharmaceuticals, Inc. a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced updates on its research and development programs…
Phase 2 studies advance following encouraging clinical data for T-cell engagers in autoimmune diseases Candid Therapeutics, Inc. a clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers (TCEs), today announced continued clinical progress with…
WHO Global Summit Forges a Bold Vision for the Future of Traditional Medicine The second WHO Global Summit on Traditional Medicine, jointly organized with the Government of India, concluded today in New Delhi, marking a major milestone for global health as it drew…
Takeda’s Zasocitinib Demonstrates Landmark Phase 3 Results in Plaque Psoriasis, Offering Hope for Clear Skin with a Once-Daily Oral Therapy and Ushering in a New Treatment Era Takeda today announced positive topline results for the two pivotal Phase 3 randomized,…
Lilly’s Orforglipron Helps Sustain Weight Loss After Switching from Injectable to Oral GLP-1 Therapy in Pivotal Phase 3 Trial Eli Lilly and Company today announced positive topline results from the ATTAIN-MAINTAIN trial. The Phase 3 study evaluated orforglipron, an investigational,…
CDC Officially Approves Delayed Hepatitis B Vaccine Dose The CDC has accepted the recommendation of its vaccine advisory committee and ended the three-decade-long practice of giving most newborn children a birth dose of the hepatitis B vaccine.The change in recommendation, announced Tuesday, leaves the…
Argenx Shares Update on UplighTED Clinical Trials of Subcutaneous Efgartigimod for Thyroid Eye Disease Argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Phase 3 UplighTED studies…